Manage subscriptions   |   FAQ   |   Report Bugs/Errors/Omissions to ors@sfu.ca
8 entries found

Alzheimer's Drug Discovery Foundation (US)

Filter By:
  • Topic
  • Deadline
  • Region
Sort By:
  • Title
  • Deadline
  • Maximum Award

Sorry, no opportunities were found, please adjust your filters or try another search

20210205

Core Funding Programs International Verified Date 21 21 days until deadline

Deadline: February 05, 2021

The ADDF provides funding to academic centers and biotechs from around the world that are advancing therapeutic and biomarker development for Alzheimer's and related dementias. ADDF has dedicated funding to several key areas: *Translational research to develop new drugs and build preclinical evidence *IND-enabling studies and early-stage clinical trials for novel and repurposed drugs *Development and validation of plasma, CSF, neuroimaging and digital biomarkers *Epidemiological studies and comparative effectiveness research Applications are reviewed throughout the year through our core programs.

20210205
2000000

Treat Frontotemporal Dementia (FTD) Fund International Verified Date 21 21 days until deadline

Deadline: February 05, 2021
Maximum Award: $2,000,000 USD

The Alzheimer's Drug Discovery Foundation (ADDF) and the Association for Frontotemporal Degeneration (AFTD) launched the Treat FTD Fund to help address these challenges, build on emerging scientific understanding of biological mechanisms underlying FTD, provide critical funding for early-stage clinical trials and stimulate the field to develop new therapies for FTD disorders.

20210319
2000000

Treat Frontotemporal Dementia (FTD) Fund International Verified Date 63 63 days until deadline

Deadline: March 19, 2021
Maximum Award: $2,000,000 USD

The Alzheimer's Drug Discovery Foundation (ADDF) and the Association for Frontotemporal Degeneration (AFTD) launched the Treat FTD Fund to help address these challenges, build on emerging scientific understanding of biological mechanisms underlying FTD, provide critical funding for early-stage clinical trials and stimulate the field to develop new therapies for FTD disorders.

20210416

Core Funding Programs International Verified Date

Deadline: April 16, 2021

The ADDF provides funding to academic centers and biotechs from around the world that are advancing therapeutic and biomarker development for Alzheimer's and related dementias. ADDF has dedicated funding to several key areas: *Translational research to develop new drugs and build preclinical evidence *IND-enabling studies and early-stage clinical trials for novel and repurposed drugs *Development and validation of plasma, CSF, neuroimaging and digital biomarkers *Epidemiological studies and comparative effectiveness research Applications are reviewed throughout the year through our core programs.

20210528

Core Funding Programs International Verified Date

Deadline: May 28, 2021

The ADDF provides funding to academic centers and biotechs from around the world that are advancing therapeutic and biomarker development for Alzheimer's and related dementias. ADDF has dedicated funding to several key areas: *Translational research to develop new drugs and build preclinical evidence *IND-enabling studies and early-stage clinical trials for novel and repurposed drugs *Development and validation of plasma, CSF, neuroimaging and digital biomarkers *Epidemiological studies and comparative effectiveness research Applications are reviewed throughout the year through our core programs.

20210730

Core Funding Programs International Verified Date

Deadline: July 30, 2021

The ADDF provides funding to academic centers and biotechs from around the world that are advancing therapeutic and biomarker development for Alzheimer's and related dementias. ADDF has dedicated funding to several key areas: *Translational research to develop new drugs and build preclinical evidence *IND-enabling studies and early-stage clinical trials for novel and repurposed drugs *Development and validation of plasma, CSF, neuroimaging and digital biomarkers *Epidemiological studies and comparative effectiveness research Applications are reviewed throughout the year through our core programs.

20211001

Core Funding Programs International Verified Date

Deadline: October 01, 2021

The ADDF provides funding to academic centers and biotechs from around the world that are advancing therapeutic and biomarker development for Alzheimer's and related dementias. ADDF has dedicated funding to several key areas: *Translational research to develop new drugs and build preclinical evidence *IND-enabling studies and early-stage clinical trials for novel and repurposed drugs *Development and validation of plasma, CSF, neuroimaging and digital biomarkers *Epidemiological studies and comparative effectiveness research Applications are reviewed throughout the year through our core programs.

20211203

Core Funding Programs International Verified Date

Deadline: December 03, 2021

The ADDF provides funding to academic centers and biotechs from around the world that are advancing therapeutic and biomarker development for Alzheimer's and related dementias. ADDF has dedicated funding to several key areas: *Translational research to develop new drugs and build preclinical evidence *IND-enabling studies and early-stage clinical trials for novel and repurposed drugs *Development and validation of plasma, CSF, neuroimaging and digital biomarkers *Epidemiological studies and comparative effectiveness research Applications are reviewed throughout the year through our core programs.


x